Table 1.
Demographics and Medication Exposures of Studied Cohort and Subgroups
| All (N=9,589) | European American, not Hispanic (N=6,986) | African American, not Hispanic (N=953) | PREDICT preemptive model target population (N=5,764)ˆ | |
|---|---|---|---|---|
|
| ||||
| Age* | 63 (55-71) | 64 (55-72) | 60 (51-68) | 65 (58-73) |
|
| ||||
| Male Sex | 5,691 (59%) | 4,264 (61%) | 433 (45%) | 3,797 (66%) |
|
| ||||
| Coronary Artery Stent | 2,410 (25%) | 1,741 (25%) | 166 (17%) | 2,410 (42%) |
|
| ||||
| PREDICT Risk Score* | 45 (33-59) | 44 (32-58) | 49 (38-62) | 53 (44-65) |
|
| ||||
| EMR Observation Time (Days)* | 2,090 (599-4561) | 2,213 (743-4627) | 3,457 (1227-5669) | 2,442 (1,017-4,810) |
|
| ||||
| Medication Exposures | ||||
| Clopidogrel | 4,684 (49%) | 3,314 (47%) | 371 (39%) | 3,428 (59%) |
| Clopidogrel or Prasugrel | 4,742 (49%) | 3,364 (48%) | 375 (39%) | 3,472 (60%) |
| Simvastatin | 5,261 (55%) | 3,774 (54%) | 571 (60%) | 3,722 (65%) |
| Any Statin | 7,460 (78%) | 5,478 (78%) | 746 (78%) | 5,052 (88%) |
| Warfarin | 2,069 (22%) | 1,605 (23%) | 199 (21%) | 1,485 (26%) |
| Thiopurine | 129 (1%) | 104 (1%) | 14 (1%) | 84 (1%) |
| Tacrolimus | 256 (3%) | 185 (3%) | 42 (4%) | 176 (3%) |
*
Median (Interquartile Range)
ˆ
PREDICT preemptive model target population, including those with history of coronary artery stent and/or with PREDICT risk score > 40, indicating a 40% likelihood of exposure to clopidogrel, warfarin or a statin over 3 years